Literature DB >> 34112899

SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy.

Maria Teresa Sandri1, Elena Azzolini1, Valter Torri2, Sara Carloni3, Chiara Pozzi1, Michela Salvatici1, Michele Tedeschi1, Massimo Castoldi4, Alberto Mantovani1,3,5, Maria Rescigno6,7.   

Abstract

Lombardy is the Italian region most affected by COVID-19. We tested the presence of plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees across 7 healthcare facilities in areas of Lombardy with different exposure to the SARS-CoV-2 epidemic. Subjects filled a questionnaire to self-report on COVID-19 symptoms, comorbidities, smoking, regular or remote working, and the exposure to COVID-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical location of the facility, ranging between 3 and 43%, consistent with the spatial variation of COVID-19 incidence in Lombardy, and correlated with family interactions. We observed a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the anti-spike antibody response. IgG positivity among smokers was lower (7.4% vs 13.5%) although without difference in IgG plasma levels. We observed 11.9% of IgG positive asymptomatic individuals and another 23.1% with one or two symptoms. Interestingly, among the IgG positive population, 81.2% of subjects with anosmia/dysgeusia and fever were SARS-CoV-2 infected, indicating that these symptoms are strongly associated to COVID-19. In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and primarily to family rather than hospital exposure.

Entities:  

Year:  2021        PMID: 34112899     DOI: 10.1038/s41598-021-91773-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

1.  Author Correction: Virological assessment of hospitalized patients with COVID-2019.

Authors:  Roman Wölfel; Victor M Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Müller; Daniela Niemeyer; Terry C Jones; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Journal:  Nature       Date:  2020-12       Impact factor: 49.962

2.  Testing Clinical Prediction Models.

Authors:  Junfeng Wang; Yue Li
Journal:  JAMA       Date:  2020-11-17       Impact factor: 56.272

3.  The anti-inflammatory cytokine response characterized by elevated interleukin-10 is a stronger predictor of severe disease and poor outcomes than the pro-inflammatory cytokine response in coronavirus disease 2019 (COVID-19).

Authors:  Brandon Michael Henry; Stefanie W Benoit; Jens Vikse; Brandon A Berger; Christina Pulvino; Jonathan Hoehn; James Rose; Maria Helena Santos de Oliveira; Giuseppe Lippi; Justin L Benoit
Journal:  Clin Chem Lab Med       Date:  2020-11-26       Impact factor: 3.694

4.  Subspecialty-Level Deep Gray Matter Differential Diagnoses with Deep Learning and Bayesian Networks on Clinical Brain MRI: A Pilot Study.

Authors:  Jeffrey D Rudie; Andreas M Rauschecker; Long Xie; Jiancong Wang; Michael Tran Duong; Emmanuel J Botzolakis; Asha Kovalovich; John M Egan; Tessa Cook; R Nick Bryan; Ilya M Nasrallah; Suyash Mohan; James C Gee
Journal:  Radiol Artif Intell       Date:  2020-09-23

5.  Factors associated with clinical severity in Emergency Department patients presenting with symptomatic SARS-CoV-2 infection.

Authors:  Sophia Newton; Benjamin Zollinger; Jincong Freeman; Seamus Moran; Alexandra Helfand; Kayla Authelet; Matthew McHarg; Nataly Montano Vargas; Robert Shesser; Joanna Cohen; Derek Cummings; Yan Ma; Andrew C Meltzer
Journal:  medRxiv       Date:  2020-12-11

6.  Serial Quantitative Chest CT Assessment of COVID-19: A Deep Learning Approach.

Authors:  Lu Huang; Rui Han; Tao Ai; Pengxin Yu; Han Kang; Qian Tao; Liming Xia
Journal:  Radiol Cardiothorac Imaging       Date:  2020-03-30

7.  Early Elevation of Fibrosis-4 Liver Fibrosis Score Is Associated With Adverse Outcomes Among Patients With Coronavirus Disease 2019.

Authors:  Fangfei Xiang; Jing Sun; Po-Hung Chen; Peijin Han; Haipeng Zheng; Shuijiang Cai; Gregory D Kirk
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

8.  Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset.

Authors:  Bin Lou; Ting-Dong Li; Shu-Fa Zheng; Ying-Ying Su; Zhi-Yong Li; Wei Liu; Fei Yu; Sheng-Xiang Ge; Qian-Da Zou; Quan Yuan; Sha Lin; Cong-Ming Hong; Xiang-Yang Yao; Xue-Jie Zhang; Ding-Hui Wu; Guo-Liang Zhou; Wang-Heng Hou; Ting-Ting Li; Ya-Li Zhang; Shi-Yin Zhang; Jian Fan; Jun Zhang; Ning-Shao Xia; Yu Chen
Journal:  Eur Respir J       Date:  2020-08-27       Impact factor: 16.671

9.  Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.

Authors:  Reinhard Dummer; Celeste Lebbé; Victoria Atkinson; Mario Mandalà; Paul D Nathan; Ana Arance; Erika Richtig; Naoya Yamazaki; Caroline Robert; Dirk Schadendorf; Hussein A Tawbi; Paolo A Ascierto; Antoni Ribas; Keith T Flaherty; Neha Pakhle; Catarina D Campbell; Daniel Gusenleitner; Aisha Masood; Jan C Brase; Eduard Gasal; Georgina V Long
Journal:  Nat Med       Date:  2020-10-05       Impact factor: 53.440

10.  Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19.

Authors:  Yafang Li; Lin Yao; Jiawei Li; Lei Chen; Yiyan Song; Zhifang Cai; Chunhua Yang
Journal:  J Med Virol       Date:  2020-04-05       Impact factor: 2.327

View more
  7 in total

1.  One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19.

Authors:  Riccardo Levi; Elena Azzolini; Chiara Pozzi; Leonardo Ubaldi; Michele Lagioia; Alberto Mantovani; Maria Rescigno
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

2.  The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients.

Authors:  Riccardo Levi; Leonardo Ubaldi; Chiara Pozzi; Giovanni Angelotti; Maria Teresa Sandri; Elena Azzolini; Michela Salvatici; Victor Savevski; Alberto Mantovani; Maria Rescigno
Journal:  Commun Med (Lond)       Date:  2021-09-17

3.  Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel.

Authors:  Maria Elena Romero-Ibarguengoitia; Diego Rivera-Salinas; Yodira Guadalupe Hernández-Ruíz; Ana Gabriela Armendariz-Vázquez; Arnulfo González-Cantú; Irene Antonieta Barco-Flores; Rosalinda González-Facio; Laura Patricia Montelongo-Cruz; Gerardo Francisco Del Rio-Parra; Mauricio René Garza-Herrera; Jessica Andrea Leal-Meléndez; Miguel Ángel Sanz-Sánchez
Journal:  PLoS One       Date:  2022-03-02       Impact factor: 3.240

4.  A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in Coronavirus Disease 2019.

Authors:  Chiara Pozzi; Riccardo Levi; Daniele Braga; Francesco Carli; Abbass Darwich; Ilaria Spadoni; Bianca Oresta; Carola Conca Dioguardi; Clelia Peano; Leonardo Ubaldi; Giovanni Angelotti; Barbara Bottazzi; Cecilia Garlanda; Antonio Desai; Antonio Voza; Elena Azzolini; Maurizio Cecconi; Alberto Mantovani; Giuseppe Penna; Riccardo Barbieri; Letterio S Politi; Maria Rescigno
Journal:  Gastro Hep Adv       Date:  2022-02-07

5.  Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries.

Authors:  Maria Elena Romero-Ibarguengoitia; Arnulfo González-Cantú; Chiara Pozzi; Riccardo Levi; Maximiliano Mollura; Riccardo Sarti; Miguel Ángel Sanz-Sánchez; Diego Rivera-Salinas; Yodira Guadalupe Hernández-Ruíz; Ana Gabriela Armendariz-Vázquez; Gerardo Francisco Del Rio-Parra; Irene Antonieta Barco-Flores; Rosalinda González-Facio; Elena Azzolini; Riccardo Barbieri; Alessandro Rodrigo de Azevedo Dias; Milton Henriques Guimarães Júnior; Alessandra Bastos-Borges; Cecilia Acciardi; Graciela Paez-Bo; Mauro Martins Teixeira; Maria Rescigno
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

6.  Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients.

Authors:  Mariam Movsisyan; Armine Chopikyan; Irina Kasparova; Gohar Hakobjanyan; Fabrice Carrat; Meline Sukiasyan; Marieta Rushanyan; Mariam Chalabyan; Sanobar Shariff; Burhan Kantawala; Anna Keshishyan; Alvard Hovhannisyan; Armine Hakobyan; Gayane Petrosyan; Armen Minasyan; Armen Muradyan; Arsene Mekinian; Konstantin Yenkoyan
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

7.  Prevalence, Persistence, and Factors Associated with SARS-CoV-2 IgG Seropositivity in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital in Northern Italy.

Authors:  Gitana Scozzari; Cristina Costa; Enrica Migliore; Maurizio Coggiola; Giovannino Ciccone; Luigi Savio; Antonio Scarmozzino; Enrico Pira; Paola Cassoni; Claudia Galassi; Rossana Cavallo
Journal:  Viruses       Date:  2021-06-03       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.